Longevity Health Holdings Announces Execution of Merger Agreement With 20/20 Biolabs

Core Viewpoint - Longevity Health Holdings, Inc. has announced a merger with 20/20 BioLabs, Inc. in an all-stock transaction aimed at enhancing its diagnostics capabilities and addressing chronic disease risks in America [1][4]. Company Overview - Longevity Health Holdings focuses on human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][10]. - 20/20 BioLabs specializes in laboratory tests for early detection and management of chronic disease risk, offering the only multi-cancer early detection blood test available for under $200 [9][10]. Merger Details - The merger is expected to close in the third quarter of 2025, pending customary closing conditions and stockholder approvals [7]. - Post-merger, 20/20 stockholders will own approximately 50.1% and Longevity stockholders will own approximately 49.9% of the combined company [7]. - The combined company will continue trading on Nasdaq under the symbol "XAGE" [1]. Financial Implications - The merger is projected to double Longevity's fiscal year 2025 revenue forecast from approximately $3-4 million to approximately $7-8 million [6][7]. - The combined company is expected to have a post-merger equity valuation of approximately $99 million, with 20/20's pre-money valuation at around $50 million [6][7]. - Anticipated operational savings and synergies are expected to exceed $1 million in fiscal year 2025 [6]. Strategic Goals - The merger aligns with Longevity's strategy to expand its footprint in diagnostics and enhance synergies with its existing product portfolio [1][4]. - The combined company aims to address the epidemic of chronic disease in America under the "Healthy Aging, Inside and Out™" initiative [1]. Management Structure - The management team of the combined company will be mutually selected, with a Board of Directors comprising three members from each company [8].